At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Staccato Placebo +2 moredrug
Likely dose
Staccato Prochlorperazine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache
In Brief
A Phase 2 clinical trial evaluating Staccato Placebo, Staccato Prochlorperazine 5 mg, and 1 other intervention for Migraine Headache, With or Without Aura. Completed, enrolled 75 participants across 1 site.
Detailed Summary
Development of Staccato Prochlorperazine for the treatment of migraine headache.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
Primary CompletionOct 2005
First PostedFeb 2008
TodayJul 2026
First PostedFeb 8, 2008
Enrollment StartMar 1, 2005
Primary CompletionOct 1, 2005
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.4 years ago
Interventions
Staccato Placebodrug
Inhaled Staccato Placebo
Staccato Prochlorperazine 5 mgdrug
Inhaled Prochlorperazine 5 mg
Staccato Prochlorperazine 10 mgdrug
Inhaled Prochlorperazine10 mg